Norway (in addition to Finland) only accepted product patents on active ingredients in medicaments from 1. January 1992.

L'introduction du Brevet Unitaire (BU) et de la Juridiction Unifiée du Brevet (JUB) a profondément transformé le paysage des brevets en Europe. Les titulaires de brevets disposent désormais de plusieurs options.

On 24th November 2011 the Court of Justice of the European Union released its important decisions in the two cases Medeva (Case C-322/10) and Georgetown (Case C-422/10).

From April, there will be more freedom in working with divisional patent applications in Europe as the abolition of the 24 month time-limit in EPO's Rule 36 enters into force.

The Advocate General Jàn Mazák today delivered his opinion in the AstraZeneca case. AstraZeneca (AstraZeneca AB and AstraZeneca plc) had appealed the judgment from the General Court of the European Union of July 2010 where the European Commission’s fine for i.a. abusing the patent system was upheld, although it was reduced to 52,5 mill EURO.

>In Norway there is a fear that the dangerous patent creature shall play with the even more dangerous biotechnology creature.

Eight years after Norway implemented the Patent Directive (Directive 98/44/EC), and four years after the Patents Act underwent some further changes when Norway acceded to the EPC, the Norwegian Ministry of Justice (MoJ) has issued a consultation paper in which some of the implemented measures are reviewed and some amendments and adjustments are proposed.

When a founder wants to sell his or her company, there is often a discrepancy between the seller's price expectations and the buyer's willingness to pay.

Apart from design products, such as furniture, interior lamps and tableware, there is a tendency to focus on patents and trademarks as the dominant types of IP right.

On May 31 2013 changes were made to the Patents Act regarding damages in patent infringement cases where the infringement was found to be wilful or negligent.

It is crucial for early-stage life sciences companies to ensure that they have title to the inventions which they rely upon.

On 3rd May 2012, Advocate General Verica Trstenjak issued her opinion in case C-130/11, also known as the Neurim case.

The EPO changed its guidelines in June 2012 and on the 24th of October 2012 the Norwegian Patent Office amended its patent guidelines. Here follows a brief outline of the amendments in Norway.

The Norwegian legal system has a framework that makes it a favourable choice of jurisdiction for the litigation of patents. A specialized venue accompanied by expert lay judges forms the basis for high quality judgements.

Patent Litigation Comparative Guide for the jurisdiction of Norway, check out our comparative guides section to compare across multiple countries